Moxolunic LP Eye Drop contains Loteprednol Etabonate 0.5% w/v, a corticosteroid with potent anti-inflammatory action, and Moxifloxacin 0.5% w/v, a broad-spectrum fluoroquinolone antibacterial. This combination provides simultaneous reduction of ocular inflammation and control of bacterial infections.
Clinically, it is indicated for inflammatory eye conditions associated with bacterial infections, such as bacterial conjunctivitis with inflammation, postoperative ocular inflammation, and keratitis. Loteprednol suppresses inflammatory mediators, while Moxifloxacin inhibits bacterial DNA synthesis, providing comprehensive therapeutic coverage.
The ophthalmic drop formulation ensures rapid ocular penetration, uniform distribution over the ocular surface, and sustained local action, making it suitable for eye hospitals, ophthalmology clinics, outpatient departments, and specialty pharmacies. Topical administration allows targeted treatment with minimal systemic exposure.
Moxolunic LP Eye Drop helps in reducing redness, swelling, and discomfort, controlling bacterial growth, preventing infection progression, and supporting faster ocular recovery. Its proven safety and efficacy under medical supervision make it a trusted dual-action therapy for inflammatory and bacterial eye conditions.